SCHEDULE: AI n M Acquires MiCo IVD, Boosts Trinity Biotech Stake to 17%

AI n M net Ltd. has acquired MiCo IVD Holdings, LLC, making it a significant beneficial owner of 17.0% of Trinity Biotech plc's Class 'A' Ordinary Shares.

Summary

• AI n M net Ltd. acquired 100% of the equity interests in MiCo IVD Holdings, LLC from DAYLI Holdings for 5,000,000,000 South Korean won on December 2, 2025.
• This acquisition makes AI n M, along with its subsidiary MiCo IVD and CEO Wonyong Park, beneficial owners of 69,450,720 Class 'A' Ordinary Shares of Trinity Biotech plc, representing 17.0% of the outstanding shares.
• The beneficial ownership includes 44,759,380 Ordinary Shares represented by 2,237,969 American Depository Shares (ADSs) and 24,691,340 Ordinary Shares issuable upon conversion of a junior convertible note.
• The percentage is calculated based on 383,881,600 outstanding Ordinary Shares as of March 15, 2025, plus the shares from the convertible note.
• An ADS Ratio Change occurred on February 23, 2024, where each ADS now represents twenty (20) Ordinary Shares, an increase from four (4).

Sentiment

Score: 6

Explanation: The filing indicates a significant, consolidated ownership stake by a new entity, AI n M, which could bring stability or new strategic direction. However, the explicit mention of potential disposition of holdings and the broad range of strategic alternatives considered introduce uncertainty, balancing the positive aspect of a committed investor.

Positives

• A new strategic investor, AI n M, has consolidated its position as a significant beneficial owner in Trinity Biotech, potentially signaling long-term interest.
• The acquisition of MiCo IVD by AI n M from DAYLI Holdings for 5,000,000,000 South Korean won demonstrates continued investment in the entity holding Trinity Biotech shares.

Negatives

• The Reporting Persons explicitly state they "may determine to dispose of all or a portion of MiCo IVD's holdings in the Issuer," which could introduce selling pressure.

Risks

• The Reporting Persons may dispose of all or a portion of their holdings in Trinity Biotech, potentially through private or public sales, including pursuant to a Resale Registration Statement or Rule 10b-5(1) trading plans.
• Future actions by the Reporting Persons could include engaging in extraordinary corporate transactions (e.g., acquisition, merger, liquidation), material asset sales or purchases, changes in business strategy, financial or governance matters, or changes to the Board or management of Trinity Biotech.
• There is no assurance that any of the potential actions outlined by the Reporting Persons will be taken, and their plans or proposals may change at any time.

Future Outlook

The Reporting Persons intend to review their investment in Trinity Biotech on an ongoing basis. They may acquire additional equity interests, retain or sell existing holdings, or distribute them. They also reserve the right to engage with Trinity Biotech's board and management to discuss various strategic alternatives, including extraordinary corporate transactions, changes in business operations, financial or governance matters, and changes to the board or management.

Management Comments

• The applicable Reporting Persons made all acquisitions as described herein for investment purposes.
• As of the date of this Schedule 13D, the Reporting Persons may determine to dispose of all or a portion of MiCo IVD's holdings in the Issuer.
• No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein.
• There can be no assurance, however, that any of the Reporting Persons will take any of the foregoing actions, and the Reporting Persons may, at any time and from time to time, review or reconsider their position and/or change their purpose and/or plans or proposals with respect thereto.

Industry Context

This filing primarily details a change in beneficial ownership of a significant stake in Trinity Biotech plc. While it doesn't directly discuss broader industry trends, the acquisition by AI n M, a company involved in wholesale and retail trade, suggests a strategic investment outside its core business, potentially indicating a belief in the long-term value or strategic importance of the diagnostics/biotech sector, or a specific interest in Trinity Biotech's assets or market position.

Stakeholder Impact

• Shareholders: The consolidation of a 17.0% stake by AI n M could influence future strategic decisions and potentially the share price, depending on AI n M's future actions (e.g., acquiring more shares or disposing of them). The explicit mention of potential disposition of holdings could create uncertainty.
• Management/Board: The Reporting Persons explicitly state their intent to communicate with the Board and management and evaluate changes to the Board or management, indicating potential future influence on corporate direction.

Next Steps

• Reporting Persons will review their investment in Trinity Biotech on an ongoing basis.
• Reporting Persons may acquire additional equity interests in Trinity Biotech.
• Reporting Persons may retain or sell all or a portion of their equity interests in Trinity Biotech.
• Reporting Persons may distribute their equity interests to other entities.
• Reporting Persons may communicate with Trinity Biotech's board, management, or other security holders.
• Reporting Persons may engage advisors to assist in reviewing their investment.
• Reporting Persons may evaluate strategic alternatives regarding Trinity Biotech, including extraordinary corporate transactions, asset sales/purchases, changes in business, financial/governance matters, or changes to the Board/management.

Key Dates

Recommendation

The filing indicates a significant change in beneficial ownership, with AI n M net Ltd. consolidating a 17.0% stake in Trinity Biotech. While this establishes a committed, large shareholder, the explicit statement that the Reporting Persons "may determine to dispose of all or a portion of MiCo IVD's holdings" introduces considerable uncertainty and potential selling pressure. Furthermore, the broad range of strategic alternatives being considered, from acquiring more shares to influencing corporate governance or even extraordinary transactions, suggests a period of potential flux. Given the dual possibilities of increased engagement or divestment, a "hold" recommendation is prudent until AI n M's specific intentions become clearer and the market can better assess the implications of their long-term strategy.

Keywords

Trinity Biotech, MiCo IVD Holdings, AI n M net Ltd., Wonyong Park, Schedule 13D, Beneficial Ownership, Class A Ordinary Shares, Convertible Note, ADS Ratio Change, Investment, SEC Filing